Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.
Yoshino presented results of a phase I study of U3-1565 at the 2013 European Cancer Conference. U3-1565 is a fully human anti-HB-EGF monoclonal antibody that targets the solid tumor, Yoshino says. The agent showed an excellent safety profile and some types of cancers showed tumor response.
Information about TAS-102, an anti-cancer drug for colorectal cancer that originated in Japan, was also presented at the conference. Yoshino says TAS-102 is an oral, nucleoside anti-tumor agent that consists of trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI) that prevents degradation of FTD.
<<< View more from the 2013 European Cancer Congress